All Articles by Author:
Bob
Newsletters
Endometrial Cancer PDX-Derived Organoids (PDXOs) and PDXs with FGFR2c Isoform Expression Are Sensitive to FGFR Inhibition
[npj Precision Oncology] Researchers reported the establishment of 16 endometrial cancer (EC) PDXOs with or without FGFR2c expression. In vitro treatment of five EC PDXOs with BGJ398 showed significant cell death in three models with FGFR2c expression.
Newsletters
Single-Cell Transcriptome Profiling of Primary Tumors and Paired Organoids of Pancreatobiliary Cancer
[Cancer Letters] The authors conducted scRNA-seq for paired primary tumors and organoids from one cholangiocarcinoma and two pancreatic ductal adenocarcinoma patients.
Newsletters
Proteome Signatures of Joint Toxicity to Arsenic (as) and Lead (Pb) in Human Brain Organoids with Optic Vesicles
[Environmental Research] Investigators utilized brain organoids with optic vesicles to systematically analyze the neurotoxicity of arsenic and lead.
Newsletters
Pathological Deficit of Cystatin B Impairs Synaptic Plasticity in EPM1 Human Cerebral Organoids
[Molecular Neurobiology] Scientists investigated the involvement of cystatin B in synaptic plasticity, using synaptosomes from human cerebral organoids as well as from rodents’ brain.
Newsletters
3D Hepatic Organoid Production from Human Pluripotent Stem Cells
[Differentiation] Researchers described the stepwise and fully 3D production of hepatic organoids from hPSCs. They optimized every differentiation step by screening for optimal concentrations and timing of differentiation signals in each differentiation step.
Newsletters
Bioprinting Using Organ Building Blocks: Spheroids, Organoids, and Assembloids
[Tissue Engineering Part A] Investigators discuss the expanding range of organ building blocks (OBB), presents the rapidly evolving collection of bioprinting and bioassembly methods using these OBB, and outlines the advantages, challenges, and future perspectives of employing OBB in organ printing.
Popular
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
[Clinical Cancer Research] Investigators evaluated responses to brentuximab vedotin (BV)+ pembrolizumab after PD-1 therapy and explored corresponding biomarkers. A total of 58 patients with metastatic cutaneous melanoma received ≥1 dose of BV + pembrolizumab.
Gameto Announces FDA IND Clearance for Fertilo, the First iPSC-Based Therapy to Enter US Phase III Clinical Trials
[Gameto (Businesswire)] Gameto announced that the US FDA has cleared its Investigational New Drug (IND) application for Fertilo, to enable the launch of the first US-based Phase III clinical trial for an iPSC-based therapy.
Current Landscape of Adoptive Cell Therapy and Challenge to Develop “Off-The-Shelf” Therapy for Hepatocellular Carcinoma
[Journal of Gastroenterology and Hepatology] The authors discuss the current status and promise of adoptive cell therapy (ACT) research in HCC, focusing on challenges in off-the-shelf ACT using primary cells or induced pluripotent stem cells with or without genetic engineering.